BRCAAway
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
- NCT03012321 ↗
- Active, not recruiting
- Northwestern University
- Deep
We haven't built an HCP commentary report on BRCAAway (olaparib plus abiraterone; olaparib in metastatic castration-resistant prostate cancer with DNA repair defects) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice.
The commentary discusses BRCAAway’s comparison of abiraterone, olaparib and their combination in first-line metastatic castration-resistant prostate cancer with BRCA or ATM alterations, including survival, progression and response measures. It covers the study’s small sample, crossover and eligibility limitations, and concerns about toxicity and possible long-term MDS/AML risks. Questions raised include whether upfront combination treatment is preferable to sequencing and whether adding a PARP inhibitor after prior androgen-receptor pathway inhibitor treatment is addressed.
Indexed commentary on BRCAAway so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 97 | |
| YouTube | 33 | |
| Podcasts | 31 | |
| Bluesky threads | 1 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Prostate Cancer Metastatic Castration-Resistant; Abnormal DNA Repair; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer
- Interventions
- Olaparib; Abiraterone Acetate; Prednisone
- Arms
- Arm I: Abiraterone + Prednisone · Active comparator
- Arm II: Olaparib · Active comparator
- Arm III: Abiraterone + Prednisone + Olaparib · Active comparator
- Olaparib · Active comparator
- Enrollment
- 70 (estimated)
- Primary outcomes
- Objective Progression Free Survival (PFS)
- Sponsor
- Northwestern University with AstraZeneca, National Cancer Institute (NCI)
- Start
- Jan 12, 2017
- Primary completion
- Oct 21, 2023
- Results posted
- No
- Registry record
- NCT03012321 · updated Jun 1, 2026
Publications
linked from the registry- Collins K, Cheng L. Reprint of: morphologic spectrum of treatment-related changes in prostate tissue and prostate cancer: an updated review. Hum Pathol. 2023 Mar;133:92-101. doi: 10.1016/j.humpath.2023.02.007. Epub 2023 Mar 8. PubMed 36898948